BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

enGene, Inc. CEO to Present at Rodman & Renshaw Healthcare Conference


8/11/2009 10:22:45 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 11, 2009) - enGene Inc., a privately held biotechnology company with a proprietary, polymer-based nucleotide delivery technology called GEMS™ (Gut Epithelial cell Modification System), announced today that Eric A. Adams, CEO, will present at the Rodman and Renshaw 11th Annual Healthcare Conference on September 11, 2009, 10:05 am (EST) at the New York Palace Hotel in New York City.

Mr. Adams will be presenting an update on the Company's plans to advance its two lead programs - GEMS-Insulin for Type 1 diabetes and GEMS-IL10 for inflammatory bowel disease (IBD). enGene recently completed a large animal study for GEMS-Insulin that demonstrated a potentially very significant breakthrough: the ability to re-establish a functioning, self-regulating in vivo insulin control system by producing and releasing insulin from the duodenum, in the proper quantity and at the appropriate time, to regulate blood glucose levels. In the GEMS-IL10 program the Company has achieved several significant milestones in showing feasibility and efficacy in animal models of IBD: demonstrating a reduction in gut inflammation, improvement in weight and expedited tissue healing in treated animals. Based on these successes and other progress in product development, Mr. Adams will be presenting the Company's plans to complete remaining animal testing and enter into human clinical trials.

More about enGene Inc. and GEMS™

enGene's GEMS technology utilizes the natural capacity of existing, normal, healthy cells in the gastrointestinal tract to produce therapeutic protein drugs by delivering nucleotides in a novel, polymer-based vector. In addition to diabetes and IBD, other applications under development for GEMS include siRNA delivery, vaccines, and delivery of therapeutic proteins to treat Type 2 diabetes and hemophilia.

Additional information about the Company is available at www.engeneinc.com.


Contacts:
enGene Inc.
Eric A. Adams
CEO
604.221.4362
604.221.4369 (FAX)
info@engeneinc.com
www.engeneinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES